PC
GILD icon

PointState Capital’s Gilead Sciences GILD Stock Holding History

PointState Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$7.26M – 92
2021
Q4 		$7.26M Buy
+100,000
New +$6.89M 0.12% 73
2021
Q3 		– Sell
-125,000
Closed -$8.61M – 156
2021
Q2 		$8.61M Buy
125,000
+50,000
+67% +$3.34M 0.15% 80
2021
Q1 		$4.85M Sell
75,000
-25,000
-25% -$1.61M 0.1% 100
2020
Q4 		$5.83M Buy
+100,000
New +$6.03M 0.11% 87

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PointState Capital's GILD Position: Q4 2021 in Review

PointState Capital sold out of Gilead Sciences (GILD) in Q4 2021, closing a stake of 60,000 shares — an estimated $4.13M sold.

PointState Capital first reported a position in GILD in Q2 2013 and held it in 9 quarters. The position peaked at $86.6M in Q1 2018. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.

  • PointState Capital reported no remaining Gilead Sciences position as of Q4 2021 after selling out during the quarter.
  • PointState Capital sold 60,000 Gilead Sciences shares in Q4 2021, an estimated $4.13M.
  • PointState Capital first reported a position in Gilead Sciences in Q2 2013 and held it in 9 quarters.
  • PointState Capital's Gilead Sciences position peaked at $86.6M in Q1 2018.
  • 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.

Based on PointState Capital's 13F filing for Q4 2021, filed 11 Feb 2022.